07

2024

-

08

Nat Immunol | Fudan University Zhou Zhaacai/Jiao Shi shows that p97-Npl4 complex plays an important role in controlling the balance of Treg-TH17 cells in tumors

Author:


Targeting tumor-infiltrating regulatory T cells (TI-Treg) is a potential cancer treatment strategy. Complexes of ATPase p97 with cofactors (such as Npl4) have been studied as targets for anti-tumor drugs; however, whether p97 plays a role in immune cells or immunotherapy is unclear.

On August 6, 2024, Zhou Zhaocai and Jiao Shi of Fudan University jointly communicated inNature Immunology(IF=27.7)Published online entitled“Targeting p97–Npl4 interaction inhibits tumor Treg cell development to enhance tumor immunity”The research paper,The studyIt is proved that tunzobromide (thonzonium bromide) is an inhibitor of the interaction between p97 and Npl4, and this p97-Npl4 complex in TI-TregIt has key functions in cells.

Tonzobromide enhances antitumor immunity without affecting peripheral Tregcellular homeostasis. p97-Npl4 complexes link Stat3 with the E3 ligases PDLIM2 and PDLIM5, thereby promoting Stat3 degradation and enablingTI-T reg.Cell development.Collectively, this work shows the p97-Npl4 complex in controlling tumor Treg-T H17 important role in cellular homeostasis and identified possible targets for immunotherapy.

The evolutionarily conserved ATPase complex with multiple cellular activity (AAA) superfamily ATPase p97, also known as valosin-containing-containing protein (Vcp) and Cdc48, is involved with various cofactors in a wide range of cellular processes, including endoplasmic reticulum (ER)-associated degradation, mitochondrial-associated degradation, homotypic membrane fusion, DNA repair, cell cycle regulation, autophagy 7, and protein aggregation. The co-factors of p97 such as Npl4, Ufd1, p47 and Faf1 may help to recruit the substrate, while others such as Ufd2, Otu1 and gp78 may help to process the substrate. Among its diverse cellular functions, the role of p97 in regulating protein homeostasis has been best studied. For example, p97 in a complex with Npl4 can extract misfolded or polyubiquitinated proteins, which are subsequently degraded by the proteasome, a process that is important for quality control of soluble membrane-associated glycosylated proteins.

TI-Tregcells are abundant in tumor tissue and inhibit the antitumor response, especially by traditional T (Tconv) cell-mediated antitumor response.TI-T in the tumor microenvironment (tumor microenvironment, TME)regIncreased cell number and Tconv/TI-TregA reduced ratio of cell numbers is associated with a poor prognosis for many cancers.TI-TregCells utilize multiple mechanisms, including the production of immunosuppressive cytokines (such as interleukin (IL)-10 and transforming growth factor (TGF)-β) and the expression of immune checkpoint molecules (such as CTLA-4, PD-1, and TIGIT), to inhibit TconvCell function, establish an immunosuppressive TME, protect cancer cells from immune surveillance, thereby promoting tumor development, and may in some cases lead to tumor hyper-progression during immune checkpoint blockade therapy.

Blocking p97-Npl4 interactions inhibits TI-Tregcell infiltration and differentiation

Thus, inhibiting TI-Treg cell activity or eliminating TI-T regcell is a potentially important strategy in tumor immunotherapy. However, for TI-TregA major concern for cells is the risk of autoimmunity, which may be caused by systemic TregCaused by cell exhaustion or dysfunction.For TI-T regThe most challenging problem of anti-tumor immunotherapy of cells is how to distinguish between TI-T regcells and peripheral T regcells and T convcells, and most importantly how to selectively target TI-T reg.cells, while maintaining T convCell function within the TME and peripheral immune homeostasis outside the TME.
In this study, the authors have identified the p97-Npl4 complex in TI-T regfunction in cell differentiation and recruitment. thonzonium bromide (TB) was found to be a highly selective inhibitor that blocks p97-Npl4 interactions rather than targeting p97 enzymatic activity, potentially avoiding the side effects associated with other p97 inhibitors. TB Selectively Eliminates TI-T regcells, but promote the production of IL-17 helper T in TME (T H17) cell differentiation, thereby significantly enhancing anti-tumor immunity. Importantly, TB to TI-T regcells with specific inhibition without affecting T convcellular and peripheral T regCells. Thus, p97-Npl4 complex is a promising drug target that can be addressed by eliminating TI-Tregcells and enhance TH17 cells to carry out anti-tumor immunotherapy, and TB is a new way to target p97-Npl4 complex therapy.

Zhou Zhaocai and Jiao Shi, professors of the School of Life Sciences of Fudan University, are the co-authors of the paper; researchers from Fudan University, Tongji University and the First Affiliated Hospital of Kunming Medical University jointly completed the study; postdoctoral Nie Pingping and Cao Zhifa, doctoral student Yu Ruixian, and Dr. Dong Chao, director of the Department of Oncology, are the co-first authors of the paper. Professor Yufang from Suzhou University, Professor Li Bin from Shanghai Jiaotong University, researcher Liu Xiaolong and researcher Zhao Yun from the Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences, and researcher Wang Ying from the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences provided strong support for the research.

Chongqing Chongfan Technology Co., Ltd. Optical platform film thickness meter OCT optical coherence tomography LabVIEW control